COMPASS THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
COMPASS THERAPEUTICS, INC. (CMPX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $98.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $11.00K.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $87.00K, a 98.41% decline year-over-year.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$312.00K, a 157.88% decline year-over-year.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$4.02M.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$5.12M, a 205.33% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $4.86M.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$6.76M, a 220.94% decline from fiscal 2022.
- COMPASS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $5.59M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $98.00K 10-Q · filed 2026-08-06 | -$214.00K derived: sum of 3 quarters · filed 2026-08-06 | -$4.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $87.00K 10-Q · filed 2026-05-05 | -$225.00K derived: sum of 2 quarters · filed 2026-05-05 | -$4.25M derived: sum of 3 quarters · filed 2026-05-05 | -$10.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$4.33M derived: sum of 2 quarters · filed 2026-03-05 | -$10.60M derived: sum of 3 quarters · filed 2026-08-06 | -$5.12M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$10.29M derived: sum of 2 quarters · filed 2026-08-06 | -$4.80M 10-Q · filed 2025-11-05 | -$4.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$6.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$783.00K 10-Q · filed 2026-08-06 | -$244.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.48M 10-Q · filed 2026-05-05 | $6.02M derived: sum of 2 quarters · filed 2026-05-05 | $4.44M derived: sum of 3 quarters · filed 2026-05-05 | $9.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $539.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.04M derived: sum of 2 quarters · filed 2026-03-05 | $3.92M derived: sum of 3 quarters · filed 2026-03-05 | $4.86M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.38M derived: sum of 2 quarters · filed 2025-11-05 | $4.32M 10-Q · filed 2025-11-05 | $2.86M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.90M 10-Q · filed 2025-08-11 | $4.44M derived: sum of 3 quarters · filed 2025-08-11 | $799.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $936.00K 10-Q · filed 2025-05-08 | -$525.00K derived: sum of 2 quarters · filed 2025-05-08 | -$4.16M derived: sum of 3 quarters · filed 2025-05-08 | -$6.08M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$5.10M derived: sum of 2 quarters · filed 2025-02-27 | -$7.01M derived: sum of 3 quarters · filed 2025-02-27 | -$6.76M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$5.55M derived: sum of 2 quarters · filed 2024-11-12 | -$5.30M 10-Q · filed 2024-11-12 | $929.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.66M 10-Q · filed 2024-08-12 | $4.57M derived: sum of 3 quarters · filed 2024-08-12 | $3.99M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $250.00K 10-Q · filed 2024-05-13 | $6.48M derived: sum of 2 quarters · filed 2024-05-13 | $5.91M derived: sum of 3 quarters · filed 2024-05-13 | $4.53M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $5.66M derived: sum of 2 quarters · filed 2024-03-21 | $4.28M derived: sum of 3 quarters · filed 2024-03-21 | $5.59M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$575.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.95M derived: sum of 2 quarters · filed 2023-11-09 | -$639.00K 10-Q · filed 2023-11-09 | -$1.11M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$64.00K 10-Q · filed 2023-08-03 | -$535.00K derived: sum of 3 quarters · filed 2023-08-03 | -$798.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.31M 10-Q · filed 2023-05-04 | $842.00K derived: sum of 2 quarters · filed 2023-05-04 | $579.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.95M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$734.00K derived: sum of 2 quarters · filed 2023-03-15 | $639.00K derived: sum of 3 quarters · filed 2023-03-15 | -$534.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | -$263.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.11M derived: sum of 2 quarters · filed 2022-11-09 | -$63.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $200.00K 10-Q · filed 2021-08-16 | ||
| 2021-06-20 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $200.00K 10-Q · filed 2022-08-01 | $1.01M derived: sum of 3 quarters · filed 2022-08-01 | $1.41M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | -$1.17M 10-Q · filed 2022-05-09 | -$361.00K derived: sum of 2 quarters · filed 2022-05-09 | $36.00K derived: sum of 3 quarters · filed 2022-05-09 | $994.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $812.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $1.21M derived: sum of 2 quarters · filed 2022-03-18 | $2.17M derived: sum of 3 quarters · filed 2022-03-18 | $2.19M 10-K · filed 2022-03-18 |
| 2020-09-30 | $397.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.35M derived: sum of 2 quarters · filed 2021-11-12 | $1.38M 10-Q · filed 2021-11-12 | $1.17M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $958.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $982.00K 10-Q · filed 2021-08-16 | $775.00K derived: sum of 3 quarters · filed 2021-08-16 | $219.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $24.00K 10-Q · filed 2021-04-30 | -$183.00K derived: sum of 2 quarters · filed 2021-04-30 | -$739.00K derived: sum of 3 quarters · filed 2021-04-30 | |
| 2019-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | -$763.00K derived: sum of 2 quarters · filed 2021-03-05 | -$435.00K 10-K · filed 2021-03-05 | |
| 2019-09-30 | -$556.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$228.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $328.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |